V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Candel Therapeutics Executive Compensation (FY25)

CADL · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Paul Peter Tak
Velarion Member: every covered company in one industry, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Candel Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (DEF 14A): April 29, 2026
3 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Candel Therapeutics brief$1,500Get the executive brief
Velarion Member, one year
112 figures on this page, cited to the filing that reported them. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Paul FMedSci → Paul Peter Tak

Frequently asked questions

Answers drawn from the data on this page.
Who is Candel Therapeutics' chief executive and what were they paid?
Paul Peter Tak, Chief Executive Officer, President and Director, received $5,344,561 in total compensation for fiscal 2025.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Paul FMedSci
Chief Executive Officer
◇—◇◇◇—◇◇
Francesca Barone
Chief Scientific Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Paul FMedSci
Chief Executive Officer
◇—◇◇◇—◇◇
Francesca Barone
Chief Scientific Officer
◇—◇◇◇—◇◇
Jason Amello
Former Chief Financial Officer
Departed during or after this year
◇—◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Paul FMedSci
Chief Executive Officer
◇———◇—◇◇
Francesca Barone
Chief Scientific Officer
◇———◇—◇◇
Seshu Tyagarajan
Chief Technical and Development Officer
◇———◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Paul Peter Tak
Chief Executive Officer, President and Director
◇——◇◇—◇◇
Francesca Barone
Chief Scientific Officer
◇——◇◇—◇◇
Charles Schoch
Chief Financial Officer, Treasurer and Secretary
◇——◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Paul Peter TakOption◇—◇2/28/2032
Option◇—◇4/28/2033
Option◇—◇2/12/2035
Francesca BaroneOption◇—◇2/2/2032
Option◇—◇2/28/2032
Option◇—◇4/28/2033
Option◇—◇2/12/2035
Charles SchochOption◇—◇4/28/2033
Option◇—◇2/12/2035
Option◇—◇6/20/2035
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Francesca Barone
Chief Scientific Officer · Employment agreement
Severance multiple◇
Paul Peter Tak
Chief Executive Officer, President and Director · Employment agreement
Severance multiple◇
Change-in-control multiple◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Maha Radhakrishnan, M.D
◇—◇———◇
Paul B. Manning
◇—◇———◇
Christopher Martell
◇—◇———◇
Nicoletta Loggia, Ph.D., R.Ph
◇—◇———◇
Edward J. Benz Jr., M.D
◇—◇———◇
Renee Gaeta
◇—◇———◇
Joseph C. Papa, R.Ph., M.B.A
◇—◇———◇
Gary J. Nabel, M.D., Ph.D
◇—◇———◇
Paul Peter Tak, M.D., Ph.D., FMedSci served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Paul Peter Tak (Chief Executive Officer, President and Director), FY2025 total compensation $5,344,561 (base salary $743,592) [exec_comp, SEC accession 0001193125-26-191506, filed 2026-04-29]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Candel Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Candel Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Candel Therapeutics' disclosed peer group is defensible, who names Candel Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
112 figures on this page, cited to the filing that reported them.
112 cited to the filing

Documents cited

  1. 0001193125-26-191506
    Employment Agreements
  2. 0000950170-25-060093
  3. 0001193125-24-150379
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Candel Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CADL (accessed 2026).
Short form: data: Velarion

The Candel Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Candel Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy